Abstracts tagged "IL-1"

Abstract Number: 028 • 2020 Pediatric Rheumatology Symposium
A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease
Laura Schanberg¹, Peter Nigrovic ², Ashley Cooper ³, Winn Chatham ⁴, Shoghik Akoghlanian ⁵, Namrata Singh ⁶, C. Egla Rabinovich ⁷, Akaluck Thatayatikom ⁸, Alysha Taxter ⁹, Jonathan Hausmann ¹⁰, Milan Zdravkovic ¹¹, Sven Ohlman ¹¹, Henrik Andersson ¹¹, Susanna Cederholm ¹², Gunilla Huledal ¹¹, Rayfel Schneider ¹³ and Fabrizio De Benedetti ¹⁴, ¹Duke Children's Hospital & Health Center, Durham, North Carolina, ²Boston Children's Hospital, Boston, Massachusetts, ³Children's Mercy Kansas City, Kansas City, ⁴University of Alabama at Birmingham, Birmingham, ⁵Nationwide Children's Hospital, Columbus, ⁶University of Iowa Hospitals and Clinics, Iowa, Iowa, ⁷Duke University Hospital, Durham, ⁸University of Florida, Gainesville, ⁹Wake Forest Baptist Medical Center, Winston-Salem, ¹⁰Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, ¹¹Sobi, Stockholm, Sweden, ¹²Stockholm, Sweden, ¹³The Hospital for Sick Children, Toronto, Canada, ¹⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) are rare systemic disorders of auto-inflammatory nature. There is a growing understanding that SJIA…
Abstract Number: 2905 • 2019 ACR/ARP Annual Meeting
Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial
Allan Klein ¹, David Lin ², Paul Cremer ¹, Saifullah Nasir ³, Sharon Crugnale ⁴, Larisa Collins ⁴, Fang Fang ⁴, Anna Beutler ⁴ and John F Paolini⁴, ¹Cleveland Clinic, Cleveland, OH, ²Minneapolis Heart Institute - Minneapolis, Minneapolis, MN, ³Stat! Cardiologist, Chicago, IL, ⁴Kiniksa Pharmaceuticals Corp, lexington, MA
Background/Purpose: Recurrent pericarditis (RP) is characterized by the recurrence of pericarditis signs and symptoms after a symptom-free period of ≥4 to 6 weeks and affects…
Abstract Number: 1238 • 2019 ACR/ARP Annual Meeting
Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter
Félix Renaudin ¹, Laure Campillo-Gimenez ², Florence Castelli ³, François Fenaille ³, Aurélie Prignon ⁴, Christele Combes ⁵, Martine Cohen-Solal ¹, Frédéric Lioté ⁶ and Hang Korng Ea¹, ¹Université Paris, INSERM UMR1132 BIOSCAR, Paris, France, ²Université Paris, INSERM UMR1132 BIOSCAR, San Diego, ³CEA Paris-Saclay, Laboratoire d’Etudes du Métabolisme des Médicaments, Saclay, France, ⁴UMS28 Phénotypage du petit animal, Laboratoire d'Imagerie Moléculaire Positonique (LIMP), Sorbonne Univerity, Paris, France, ⁵CIRIMAT, Université de Toulouse, INPT,UPS,CNRS,ENSIACET, Toulouse, France, ⁶Rheumatology Department, Lariboisiere Hospital, AP-HP, Paris, France, Paris, France
Background/Purpose: Monosodium urate (MSU) andmonoclinic calcium pyrophosphate dihydrated(mCPPD)crystals are responsible for relapsing acute arthritis which is driven by interleukin 1β (IL-1β).IL-1βproductionrelies onNLRP3 inflammasome activationleading to…
Abstract Number: 1985 • 2018 ACR/ARHP Annual Meeting
IL-1β Inhibits the Expression of Dickkopf-1, an Antagonist of the Wnt-β-Catenin Signaling Pathway: A Possible Role of Inflammasome in Dysregulation of Endochondral Ossification
Satoshi Yamasaki¹, Yusuke Yoshida², Katsuhiro Oi², Tatsuomi Kuranobu², Takaki Nojima², Hiroaki Ida³ and Eiji Sugiyama⁴, ¹Division of Rheumatology, Kurume University Medical Center, Fukuoka, Japan, ²Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ³Respiorogy, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, ⁴Department of Clinical Immunology and Rheumatology, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Aberrant endochondral bone formation in the physis is a unique bone lesion in neonatal-onset multisystem inflammatory disease (NOMID), also called chronic infantile neurologic cutaneous…
Abstract Number: 2855 • 2018 ACR/ARHP Annual Meeting
Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira
Jasmin B. Kuemmerle-Deschner¹, Konstanze Hoertnagel², Susanne Schlipf³, Sandra Hansmann⁴, Toni Hospach⁵, Ilias Tsiflikas⁶, Xiao Liu⁷, Susanne Benseler⁸ and Alexander Weber⁷, ¹Department of Pediatrics, Division of Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ²Praxis für Humangenetik Tübingen,Tuebingen, Germany, Tuebingen, Germany, ³Kinderarztpraxis Dr. Lakner, Schwäbisch Gmünd, Germany, Schwäbisch Gmünd, Germany, ⁴Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, Tuebingen, Germany, ⁵Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, ⁶Division of Pediatric Radiology, Department of Radiology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ⁷Department of Immunology, University of Tübingen, Tübingen, Germany, Tuebingen, Germany, ⁸Rheumatology, Department of Paediatrics, Alberta Children's Hospital, University of Calgary, Alberta, Canada, Calgary, AB, Canada
Background/Purpose: Deficiency of the Interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease of infancy characterized by severe systemic inflammation with bone and skin involvement. This…
Abstract Number: 2965 • 2018 ACR/ARHP Annual Meeting
Targeting Glucose Metabolism in the Murine Air Pouch Model of Acute Gouty Inflammation
Anyan Cheng¹, Roxana Coras^1,2, Robert Terkeltaub^3,4, Ru Liu-Bryan^1,3 and Monica Guma^1,2, ¹Medicine, University of California San Diego, La Jolla, CA, ²Medicine, Autonomous University of Barcelona, Bellatera, Spain, ³VA San Diego Healthcare System, San Diego, CA, ⁴Medicine, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA
Background/Purpose: Emerging evidence indicates that macrophage activation is critically supported by glucose metabolic shifts. Although macrophages are key contributors to inflammation, little is known about…
Abstract Number: 2968 • 2018 ACR/ARHP Annual Meeting
Role of Choline in Gouty Inflammation
Elsa Sanchez-Lopez¹, Zhenyu Zhong¹, Alex Stubelius², Shannon R Sweeney³, Ru Liu-Bryan^4,5, Juan Carlos Lacal⁶, Stefano Tiziani^3,7,8, Robert Terkeltaub^4,9, Monica Guma⁹ and Michael Karin¹, ¹Department of Pharmacology, School of Medicine. UCSD., La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA, ³Department of Nutritional Sciences. The University of Texas at Austin., Austin, TX, ⁴VA San Diego Healthcare System, San Diego, CA, ⁵Medicine-Rheumatology, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA, ⁶Translational Oncology. Department of Oncology, Hospital Universitario Fuenlabrada, Madrid, Spain, ⁷Department of Molecular Biosciences, College of Natural Sciences. The University of Texas at Austin., Austin, TX, ⁸Department of Pediatrics, Dell Medical School. The University of Texas at Austin., Austin, TX, ⁹Medicine, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA
Background/Purpose: Gout is characterized by deposition of monosodium urate (MSU) crystals in articular joints, where they activate macrophages inducing NLRP3 inflammasome activation and bioactive IL-1β…
Abstract Number: 76 • 2017 ACR/ARHP Annual Meeting
TNF-α Potentiates Uric Acid-Induced Interleukin-1β Secretion in Human Neutrophils
Shuzo Sato¹, Makiko Yashiro¹, Tomoyuki Asano¹, Tomohiro Koga², Eiji Suzuki¹, Hiroko Kobayashi¹, Hiroshi Watanabe¹ and Kiyoshi Migita³, ¹Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Fukushima Medical University School of Medicine, Fukushima, Japan
Background/Purpose: Gout is an inflammatory arthropathy due to the deposition of uric acid (monosodium urate: MSU) crystals in synovial tissue. MSU leads to activate nucleotide-binding…
Abstract Number: 77 • 2017 ACR/ARHP Annual Meeting
Platelets Induce IL-1b Production in Human Monocytes through NLRP3 Inflammasome Activation
Shota Nakano¹, Hiroki Mitoma¹, Shotaro Kawano¹, Shoichiro Inokuchi², Masahiro Ayano¹, Yasutaka Kimoto³, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi⁴ and Hiroaki Niro⁵, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Recent studies have revealed that platelets play pivotal roles in inflammation in addition to hemostasis. The thrombus induces subsequent local inflammation and reversely the…
Abstract Number: 1163 • 2017 ACR/ARHP Annual Meeting
A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects
Ahmet Gul¹, Sibel Ulker², Recep Selim Senturk², Ugur Onsel Turk², Cemil Gurgun², Yan Lavrovsky³, Mikhail Samsonov⁴, Sebnem Ozen⁵ and Serdar Altinel⁶, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Ege University Drug Development and Pharmacokinetics Research and Application Centre (ARGEFAR), Izmir, Turkey, ³R-Pharm Overseas, Inc.,, San Diego, CA, ⁴Medical Department, R-Pharm JSC, Moscow, Russian Federation, ⁵Clinical Trial Department, TRPHARM İlac A.S., Istanbul, Turkey, ⁶linical Trial Department, TRPHARM İlac A.S., Istanbul, Turkey
Background/Purpose: Interleukin-1 (IL-1) is highly active pro-inflammatory cytokine, which is responsible for clinical and laboratory findings in hereditary and acquired auto-inflammatory disorders. Blocking IL-1 activity…
Abstract Number: 1196 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of ABT-981, an Anti–Interleukin-1α/β Dual Variable Domain (DVD) Immunoglobulin, in Subjects with Knee Osteoarthritis: Results from the Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Trial
Roy Fleischmann¹, Henning Bliddal², Francisco J Blanco³, Thomas J. Schnitzer⁴, Charles Peterfy⁵, Su Chen⁶, Li Wang⁶, Philip G. Conaghan⁷, Francis Berenbaum⁸, Jean-Pierre Pelletier⁹, Johanne Martel-Pelletier⁹, Ole Vaeterlein¹⁰, Wei Liu⁶, Gwen Levy⁶, Lanju Zhang⁶, Jeroen K. Medema⁶ and Marc C. Levesque⁶, ¹University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, ²Parker Institute, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark, ³INIBIC-Instituto de Investigaciones Biomédicas de A Coruña-Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain, ⁴Northwestern Medicine, Feinberg School of Medicine, Chicago, IL, ⁵Spire Sciences, Inc., Boca Raton, FL, ⁶AbbVie Inc., North Chicago, IL, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁸University Pierre & Marie Curie and Inserm, DHU i2B, APHP, Hospital Saint-Antoine, Paris, France, ⁹Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, ¹⁰Bioclinica, Hamburg, Germany
Background/Purpose: Animal studies suggested that inhibiting IL-1α/β with ABT-981 may reduce pain and slow structural progression in OA. This study (NCT02087904; ILLUSTRATE-K) assessed the safety…
Abstract Number: 1211 • 2017 ACR/ARHP Annual Meeting
Biomarkers Predictive of Pain Improvement in Knee Osteoarthritis Subjects Treated with the Anti-IL-1α/β Dual Variable Domain Immunoglobulin ABT-981
Sheng Feng¹, Su Chen¹, Li Wang¹, Charles Peterfy², Virginia B. Kraus³, Rajesh Kamath¹, Lanju Zhang¹, Yanping Luo¹, Lu Cui¹, Jeroen K. Medema¹ and Marc C. Levesque¹, ¹AbbVie Inc., North Chicago, IL, ²Spire Sciences, Inc., Boca Raton, FL, ³Duke University School of Medicine, Durham, NC
Background/Purpose: Development of disease-modifying drugs for OA has been challenging, partly due to lack of predictive biomarkers. Our primary objective was to identify baseline (BL)…
Abstract Number: 2083 • 2017 ACR/ARHP Annual Meeting
The Inflammation Induced By Four Types of Calcium Pyrophosphate Crystals Depends on Their Capacity to Stimulate NF-κb and MAPK Pathways
Félix Renaudin¹, Laure Campillo-Gimenez², Pierre Gras³, Christèle Combes⁴, Martine Cohen-Solal¹, Frederic Liote⁵ and Hang-Korng Ea¹, ¹INSERM UMR1132, Paris Diderot University, Paris, France, ²Inserm UMR1132 Bioscar, Paris, France, ³CIRIMAT, INPT-UPS-CNRS, Toulouse, France, ⁴ENSIACET, CIRIMAT, INPT-UPS-CNRS, Toulouse, France, ⁵University Paris Diderot, Paris, France
Background/Purpose: Calcium pyrophosphate (CPP) crystal-induced inflammation is mainly driven by interleukin (IL)-1β. IL-1β production involves a two-step process including the formation of pro-IL-1β through NF-κB…
Abstract Number: 74 • 2017 Pediatric Rheumatology Symposium
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Esraa M. A. Eloseily^1,2, Peter Weiser¹, Hilary Haines³, Melissa Mannion⁴, Matthew L. Stoll¹, Timothy Beukelman¹, Prescott Atkinson⁵ and Randy Q. Cron¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Assiut University, Assiut, Egypt, ³Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatric Allergy and Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Familial, or primary, hemophagocytic lymphohistiocytosis (pHLH), is a rare but highly fatal condition due to mutations in lymphocyte cytolytic pathway genes. Secondary HLH (sHLH),…
Abstract Number: 3 • 2017 Pediatric Rheumatology Symposium
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis: Results From an Open-Label, Long-Term Follow-up Study
Hermine Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamás Constantin², Ekaterina Alexeeva², Rayfel Schneider⁴, Isabelle Koné-Paut⁵, Kenneth N. Schikler⁶, Katherine Marzan⁴, Nico Wulffraat², Shai Padeh⁷, Vyacheslav Chasnyk⁷, Carine Wouters⁷, Jasmin B. Kuemmerle-Deschner⁷, Tilmann Kallinich⁷, Bernard Lauwerys⁸, Elie Haddad⁴, Evgeny L Nasonov⁷, Maria Trachana⁷, Olga Vougiouka⁷, Karolynn Leon⁹, Antonio Speziale¹⁰, Karine Lheritier¹⁰, Eleni Vritzali¹¹, Alberto Martini⁷ and Daniel Lovell⁴, ¹Rheumatology, PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genoa, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴PRCSG, Cincinnati, OH, ⁵Hôpital Kremlin Bicetre, University of Paris SUD, Paris, France, ⁶PRCSG, Cincinatti, OH, ⁷PRINTO-Istituto Gaslini, Genova, Italy, ⁸Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Immunology and Dermatology Franchise, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a selective human anti-IL1 β monoclonal antibody, had demonstrated its efficacy and safety in patients (pts) with active systemic juvenile idiopathic arthritis…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].